Clinical Trial Update: Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis

View source ↗

Summary

Pfizer's expanded access protocol for abrocitinib in adolescents and adults with moderate-to-severe atopic dermatitis is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Abrocitinib (abrocitinib)

Snippet

Sponsor: Pfizer | Conditions: Atopic Dermatitis | Status: NO_LONGER_AVAILABLE